The ReSPonD trial - rivastigmine to stabilise gait in Parkinson’s disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson’s disease who have fallen

BACKGROUND: Gait impairment is common in people with Parkinson’s disease. There is a lack of effective interventions to target this debilitating complication and therefore a need to identify new therapeutic options. An underlying cholinergic deficit contributes to both the gait and cognitive dysfunc...

Descripción completa

Detalles Bibliográficos
Autores principales: Henderson, Emily J, Lord, Stephen R, Close, Jacqueline CT, Lawrence, Andrew D, Whone, Alan, Ben-Shlomo, Yoav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880104/
https://www.ncbi.nlm.nih.gov/pubmed/24299497
http://dx.doi.org/10.1186/1471-2377-13-188

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880104/
https://www.ncbi.nlm.nih.gov/pubmed/24299497
http://dx.doi.org/10.1186/1471-2377-13-188

Ejemplares similares